EconomyEditor's PickNewsNovavax Rises as Covid Vaccine Candidate Enters Late-Stage Trial

2 years ago295 min
https://topinvestingtoday.com/wp-content/uploads/2021/12/cover-8-1280x813.jpg
imageStock Markets40 minutes ago (Sep 25, 2020 10:52AM ET)

(C) Reuters.

By Christiana Sciaudone

Investing.com — Novavax (NASDAQ:NVAX) is up 13% Friday after saying it will begin a late-stage trial of its Covid-19 vaccine candidate.

The Phase 3 study to evaluate NVX-CoV2373 is expected to enroll and immunize up to 10,000 individuals between 18 and 84 over the next four to six weeks in the U.K.

“With a high level of SARS-CoV-2 transmission observed and expected to continue in the UK, we are optimistic that this pivotal Phase 3 clinical trial will enroll quickly and provide a near-term view of NVX-CoV2373’s efficacy,” said Novavax President Gregory M. Glenn. “The data from this trial is expected to support regulatory submissions for licensure in the UK, EU and other countries.”

The vaccine can be stored unfrozen at 2?C to 8?C, allowing for distribution using standard vaccine channels. Novavax has continued to scale-up its manufacturing capacity, currently at up to 2 billion annualized doses, once all capacity has been brought online by mid-2021.

The trial is designed to enroll at least 25% of participants over the age of 65 as well as to prioritize groups that are most affected by Covid-19, including racial and ethnic minorities.

Novavax Rises as Covid Vaccine Candidate Enters Late-Stage Trial

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Leave a Reply

Your email address will not be published. Required fields are marked *